Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
From 1 February 2024, Opdualag® will be available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of advanced melanoma. Opdualag® is a combination of two immune checkpoint inhibitors, nivolumab and relatlimab. Nivolumab inhibits…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for lumacaftor plus ivacaftor (Orkambi®) has recently been expanded to include patients from one year of age. This medicine is indicated for the treatment of cystic fibrosis in…
Read more
Enfortumab vedotin has recently been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of locally advanced or metastatic urothelial cancer that has progressed despite therapy. Urothelial cancer begins in the urothelial cells,…
Read more
Andexanet alfa has provisional approval for the reversal of anticoagulation in adult patients who experience life-threatening or uncontrolled bleeding with a direct factor Xa inhibitor (apixaban or rivaroxaban). Andexanet alfa is a recombinant form…
Read more
Trastuzumab deruxtecan has been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. Around 15-20% of all breast cancers are HER2 positive,…
Read more
The Therapeutic Goods Administration (TGA) has published a safety alert regarding the use of high doses of baclofen. This alert has been issued following recent coronial inquiries into two deaths. Baclofen is a skeletal…
Read more
